Linezolid Effects on Bacterial Toxin Production and Host Immune Response: Review of the Evidence  by Diep, Binh An et al.
1B
p
i
t
a
i
d
i
t
l
i
a
c
o
l
o
c
i
i
s
Current Therapeutic Research
VOLUME , NUMBER , JUNE Linezolid Effects on Bacterial Toxin Production and
Host Immune Response: Review of the Evidence
Binh An Diep, PhD1; Ozlem Equils, MD2; David B. Huang, MD, PhD2; and
Ron Gladue, MS3
Department of Medicine, University of California at San Francisco, San Francisco,
California; 2Medical Division, Pfizer Inc, Collegeville, Pennsylvania; and 3Pfizer Global
iotherapeutic Technologies, Cambridge, Massachusetts
ABSTRACT
Background: Linezolid is active against a broad range of gram-positive
athogens and has the potential to also affect production of bacterial toxins and host
mmune function.
Objective: To assess the evidence for direct effects of linezolid on bacterial
toxin synthesis and modulation of host immune responses.
Methods: Literature searches were performed of the PubMed and OVID data-
bases. Reviews and non–English language articles were excluded. Articles with
information on the effect of linezolid on bacterial toxin synthesis and immune
responses were selected for further review, and data were summarized.
Results: Substantial in vitro evidence supports effects of linezolid on bacterial
oxin production; however, the strength of the evidence and the nature of the effects
re mixed. In the case of Staphylococcus aureus, repeated observations support the
nhibition of production of certain staphylococcal toxins (Panton-Valentine leukoci-
in, protein A, and - and -hemolysin) by linezolid, whereas only solitary reports
ndicate inhibition (toxic shock syndrome toxin-1, coagulase, autolysins, and entero-
oxins A and B) or stimulation (phenol-soluble modulins) of toxin production by
inezolid. In the case of Streptococcus pyogenes, there are solitary reports of linezolid
nhibition (protein M, deoxyribonuclease, and streptococcal pyrogenic exotoxins A, B,
nd F) or stimulation (immunogenic secreted protein 2 and streptococcal inhibitor of
omplement-mediated lysis) of toxin production, whereas published evidence for effects
n streptolysin O production is conflicting. In vitro data are limited, but suggest that
inezolid might also have indirect effects on host cytokine expression through inhibition
f bacterial production of toxins. In vivo data from preclinical animal studies and a single
linical study in humans are limited and equivocal insofar as a potential role for linezolid
n modulating the host inflammatory response; this is due in part to the difficulty in
solating antimicrobial effects and toxin synthesis inhibitory effects of linezolid from any
econdary effects on host inflammatory response.
Conclusions: Available evidence supports the possibility that linezolid can
inhibit, and in some cases stimulate, toxin production in clinically relevant patho-
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B.A. Diep et al.gens. However, more research will be needed to determine the potential clinical
relevance of those findings for linezolid. (Curr Ther Res Clin Exp. 2012;73:86–102)
© 2012 Elsevier HS Journals, Inc. All rights reserved.
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INTRODUCTION
Bacterial toxins are important mediators of pneumonia, sepsis, and septic shock, in
part because of their effects on components of the host immune system.1 Different
classes of antibacterial agents may have different effects on the production and release
of bacterial toxins and on the subsequent immune response.2–4 Antimicrobial agents
that disrupt bacterial cell wall synthesis (-lactams) lead to bacterial death and the
release of pathogen-associated molecular patterns such as lipopolysaccharide (LPS),
lipoprotein, or DNA.5 The release of pathogen-assisted molecular patterns may
nduce more robust host immune responses. In contrast, antimicrobial agents that
nhibit the microbial ribosome system (eg, protein synthesis inhibitors such as
incomycins and oxazolidinones) or DNA gyrase (eg, fluoroquinolones) suppress the
ynthesis of bacterial toxins, and may have secondary effects on dampening toxin-
nduced host inflammatory responses.5 These antimicrobial agents are often used in
linical practice to treat toxin-mediated infections (eg, toxic shock syndrome [TSS]
nd pneumonia).5,6 Nevertheless, it remains to be determined whether the effects of
acterial protein synthesis inhibitors on either bacterial toxin production or immu-
omodulation have any effect on treatment outcomes.
Linezolid is an oxazolidinone antibiotic indicated for treatment of complicated
kin and skin structure infections caused by susceptible pathogens (eg, methicil-
in-resistant and methicillin-susceptible strains of Staphylococcus aureus (MRSA
nd MSSA, respectively), Streptococcus pyogenes, or Streptococcus agalactiae), including
iabetes-related foot infections without concomitant osteomyelitis, and nosoco-
ial pneumonia caused by MRSA or MSSA or Streptococcus pneumoniae.7 Linezolid
binds to the bacterial ribosome and prevents the formation of the 70S initiation
complex, thereby inhibiting protein synthesis.8 Linezolid is bacteriostatic against
enterococci and staphylococci and is bactericidal for most streptococci strains.7 In
addition to this activity, linezolid has been reported to inhibit bacterial toxin
production and, therefore, has the potential to indirectly modulate host immune
function during resolution of infection.9 –12 Herein, we review the evidence for
linezolid-mediated effects on bacterial toxin production and the host immune
responses in the published peer-reviewed literature and provide perspectives on
the clinical relevance of these findings.
METHODS
A retrospective literature search of the PubMed database was performed from August
through December 2011, without any year limitations, using the key words “lin-
ezolid” or “protein synthesis inhibitor antibiotic” and each of the following: “animal,”
“chemokine,” “C-reactive protein,” “cytokine,” “immune,” “inflammation,” “lipo-
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Current Therapeutic Researchpolysaccharide,” “neutrophil,” “Panton-Valentine leukocidin” (PVL), “phenol-soluble
modulins” (PSM), “Staphylococcus,” “Streptococcus,” and “toxin.” Reviews and non–
English language articles were excluded, and the remaining articles were screened
manually for relevance (ie, whether the article included data on linezolid-mediated
effects on bacterial toxin production and/or the immune system). Search results were
confirmed by performing another search of the OVID database using the same key
words noted above. All selected references were categorized as in vitro, in vivo animal,
or in vivo human. Key data were summarized and critically reviewed.
RESULTS
Literature Selection
The PubMed search yielded 48,976 articles, 841 of which were reviewed and
ssessed for relevance to this review. Results from search term combinations that
ielded more than 500 articles were discarded as not sufficiently specific. Articles with
elevant information from the remaining results were reviewed and summarized. The
onfirmatory search of the OVID database yielded no additional articles for inclusion
n this review.
Linezolid Effect on Staphylococcal Toxins
Seven articles were found that provided evidence of linezolid-mediated effects on
oxins produced by S aureus, and these are summarized below. A brief summary of the
oxins and the results from each study are also given in Table I.
anton-Valentine Leukocidin
PVL is a toxin that is characteristically produced by invasive community-associated
RSA (CA-MRSA) strains that cause diseases of the lung, bone, and soft tissues
Table I).13–17 In 2 articles, Dumitrescu et al9,10 examined the in vitro effect of
linezolid and other antibiotics on PVL production by laboratory and clinical strains
of PVL-positive MSSA and CA-MRSA. Subinhibitory concentrations of oxacillin
(one-eighth to one-half the minimum inhibitory concentrations (MIC) increased PVL
production 2- to 6.5-fold in the MSSA and MRSA strains tested. Exposure to
subinhibitory concentrations of vancomycin had no significant effect on PVL pro-
duction. In contrast, subinhibitory concentrations of clindamycin, fusidic acid, ri-
fampicin, or linezolid inhibited PVL production.9,10 Furthermore, the increased PVL
production induced by subinhibitory concentrations of oxacillin was inhibited by
co-incubation with rifampicin, clindamycin, or linezolid (at one-eighth, one-fourth,
and one-half their MIC, respectively).9
Stevens et al11 compared the effects of nafcillin (at up to one-third of its MIC)
with those of vancomycin, linezolid, and clindamycin (at 5-fold their MIC) on the
growth and expression of PVL mRNA and protein in a PVL-positive CA-MRSA
strain (Table I). Compared with untreated control cultures, nafcillin added during
log-phase growth had little or no effect on growth through the late log phase into the
stationary phase (up to 34 hours); however, it prolonged expression of PVL mRNA
and increased expression of detectable PVL protein. Vancomycin transiently inhibited
both growth and PVL mRNA expression; however, PVL protein levels were not
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Table I. Effect of linezolid on Staphylococcus aureus toxin synthesis.
Toxin and Effect Reference S aureus Strain Linezolid Concentration (MIC) and Effect
PVL: Pore-forming leukotoxin associated
with primary skin and soft tissue
infections and severe necrotizing
pneumonia
Dumitrescu et al,10 2007 PVL-positive MSSA, PVL-positive
CA-MRSA
0.125 to 1  MIC; significantly reduced production
of PVL by all strains
Dumitrescu et al,9 2008 PVL-positive MSSA 0.25 to 0.5  MIC; significantly reduced PVL
production (including oxacillin-induced
expression)
Stevens et al,11 2007 PVL-positive CA-MRSA 5  MIC; significantly reduced expression of PVL
protein but not mRNA
TSST-1: Superantigen; induces TSS Stevens et al,12 2006 MSSA 0.25 to 5  MIC; significantly reduced TSST-1
production
PSM: Activates innate immune system;
associated with severe skin infections
Joo et al,19 2010 CA-MRSA, HA-MRSA 0.1 to 0.2  MIC; significantly increased PSM
production in both strains
Protein A: Inhibits opsonophagocytosis
Gemmell and Ford,21
2002
S aureus strain expressing
virulence factors
0.5  MIC; significantly reduced protein A activity
Bernardo et al,22 2004 MSSA 0.125 to 0.9  MIC; significantly reduced protein A
secretion
Coagulase: Inhibits phagocytosis Gemmell and Ford,21
2002
S aureus strain expressing
virulence factors
0.125 to 0.5  MIC; significantly reduced
coagulase activity
- and -Hemolysins: Cause pore
formation and host cell death
Gemmell and Ford,21
2002
S aureus strain expressing
virulence factors
0.125 to 0.5  MIC; significantly reduced - and
-hemolysin activity
Bernardo et al,22 2004 MSSA 0.125 to 0.9  MIC; significantly reduced - and
-hemolysin secretion
Autolysins: Promote release of
proinflammatory peptides
Bernardo et al,22 2004 MSSA 0.125 to 0.9  MIC; significantly reduced autolysin
family protein secretion
Enterotoxin A and B: Superantigens;
induce T-cell activation
Bernardo et al,22 2004 MSSA 0.125 to 0.9  MIC; significantly reduced
enterotoxin A and B secretion
CA-MRSA  community-associated methicillin-resistant S aureus; HA-MRSA  hospital-acquired methicillin-resistant S aureus; MIC  minimum inhibitory concentration;
MSSA  methicillin-susceptible S aureus; PSM  phenol-soluble modulins; PVL  Panton-Valentine leukocidin; TSS  toxic shock syndrome; TSST-1  toxic shock syndrome
toxin-1.
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Current Therapeutic Researchdifferent from untreated control cultures at any time. In addition, linezolid and
clindamycin markedly suppressed PVL protein expression for at least 24 hours despite
the presence of significant levels of PVL mRNA.
Toxic Shock Syndrome Toxin-1
One case report was found in which staphylococcal TSS in a 56-year-old man was
initially and successfully treated using linezolid for 48 hours, then switched to
clindamycin when bacterial susceptibilities were confirmed.12 The investigators cul-
ured the patient’s S aureus isolate and tested the effects of various antibiotics on
rowth and toxic shock syndrome toxin-1 (TSST-1) production (Table I). When
ntibiotics were added to the culture at concentrations 5 times their MIC, bacterial
rowth was inhibited by nafcillin, clindamycin, or linezolid, but not vancomycin.
aximal production of TSST-1 occurred between 8 and 24 hours in untreated
ultures and was not inhibited by either vancomycin or nafcillin. In contrast, both
lindamycin and linezolid completely suppressed TSST-1 production. At a concen-
ration of one-fourth its MIC, when bacterial numbers were still high, linezolid
ontinued to significantly suppress TSST-1 production.
henol-Soluble Modulins
PSMs are secreted virulence factors that elicit proinflammatory immune responses
nd mediate neutrophil lysis.18 Joo et al19 assessed the effect on PSM production of
a range of antibiotics at concentrations that caused only minimal effects on bacterial
growth (Table I). These investigators tested one strain each of CA-MRSA and
hospital-acquired MRSA (HA-MRSA). At subinhibitory concentrations in the CA-
MRSA strain, oxacillin inhibited the productions of PSM, whereas subinhibitory
concentrations of antibiotics that target protein synthesis (erythromycin, tetracycline,
clindamycin, and linezolid) all increased PSM production. In the HA-MRSA strain,
oxacillin had no effect on PSM production, and the PSM-inducing effects of eryth-
romycin, tetracycline, clindamycin, and linezolid were less pronounced than in
CA-MRSA. Because PSM expression is controlled by the accessory gene regulator
(agr) locus (a quorum-sensing system that upregulates secretory protein expression
and downregulates surface protein expression during the transition from log phase to
stationary growth20), the investigators also tested the activity of agr by examining
expression of RNAIII and psm-operon transcripts. The effects of oxacillin, tetracy-
cline, and clindamycin on agr activity mirrored their effects on PSM production,
strongly suggesting the involvement of agr in those effects.
Other Staphylococcal Virulence Factors
Gemmell and Ford21 tested the effect of subinhibitory concentrations of linezolid
on the production of a range of toxins in S aureus including - and -hemolysins,
which lyse rabbit and human red blood cells; coagulases, which clot rabbit plasma;
and protein A, which affects susceptibility to opsonophagocytosis (Table I). At
concentrations from one-eighth to one-half MIC, linezolid inhibited the activity of
coagulase and - and -hemolysins in S aureus. At one-half MIC, linezolid signifi-
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protein A.
Bernardo et al22 used protein assays to examine the effect of subinhibitory con-
entrations of linezolid on the secretion of proteins by MSSA (Table I). With 1- and
-dimensional gel electrophoresis techniques, concentrations of linezolid from 12.5%
o 90% of its MIC added during log-phase growth reduced the secretion of high-
olecular-weight proteins. Spectroscopic techniques were applied to identify selected
roteins that had been reduced. Among those were protein A, - and -hemolysins,
and autolysin family proteins, which promote release of proinflammatory peptides.
Western blot analysis was used to show that staphylococcal enterotoxins A (SEA) and
B, which cause gastritis and T-cell proliferation, were also reduced. To test the effects
of linezolid on the proinflammatory activity of toxins secreted from MSSA, superna-
tants of bacterial cultures incubated with concentrations of linezolid from 12.5% to
90% MIC were added to murine splenic or peritoneal macrophages to examine the
effect on production of tumor necrosis factor- (TNF-), a proinflammatory mediator
produced by activated macrophages. Culture supernatants of S aureus treated with
linezolid inhibited TNF- production in macrophages, whereas linezolid alone (no
S aureus culture supernatant) did not affect TNF- production by the macrophages.
hese data suggest that linezolid has no direct effect on macrophages but that its
uppression of TNF- production by macrophages was due to an indirect effect on
bacterial production of toxins that can induce a proinflammatory response in these
cells.
Streptococcal Toxins
Eight articles were found that provided evidence of linezolid-mediated effects on
oxins produced by S pyogenes; these are summarized below. A brief summary of the
oxins and the results from each study are also given in Table II.
In addition to their research on S aureus toxins, Gemmell and Ford21 also tested the
effects of subinhibitory concentrations of linezolid on the activity of toxins produced
by S pyogenes, including protein M, streptolysin O (SLO), and deoxyribonuclease
(DNase) (Table II). As also used by these investigators in their analysis of S aureus
toxins, the assays used in this analysis were indirect and included cell lysis (SLO),
DNA agar dissolution (DNase), or opsonophagocytosis (protein M). At concentrations
from one eighth to one half its MIC, linezolid inhibited the activities of SLO and
DNase and increased susceptibility to opsonophagocytosis.
Tanaka et al23 used 1- and 2-dimensional gel electrophoresis to analyze the effects
of subinhibitory concentrations of a range of antibiotics that included benzylpenicil-
lin, linezolid, and clindamycin on the production of exoproteins by S pyogenes (Table
II). In supernatants from late stationary-phase cultures, the exoprotein profile from
benzylpenicillin-treated cultures was not remarkably different from untreated con-
trols. In cultures treated with protein synthesis inhibitors including clindamycin,
linezolid, kanamycin, tetracycline, chloramphenicol, and erythromycin, the exopro-
tein profile demonstrated reduced production of streptococcal pyrogenic exotoxin
(Spe) B (reduced between one half to less than one eighth), and most of those agents
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However, levels of several exoproteins were increased by this class of antibiotics. For
Table II. Effect of linezolid on Streptococcus pyogenes toxin synthesis.
Toxin and Effect Reference S pyogenes Strain
Linezolid
Concentration (MIC)
and Effect
Protein M: Inhibits
opsonophagocytosis
Gemmell and
Ford,21 2002
S pyogenes strain
expressing
virulence factors
0.125 to 0.5  MIC;
significantly reduced
protein M activity
treptolysin O: Causes
pore formation and
host cell death
Gemmell and
Ford,21 2002
S pyogenes strain
expressing
virulence factors
0.125 to 0.5  MIC;
significantly reduced
streptolysin O
activity
Tanaka et al,23
2005
S pyogenes
M1 (clinical
isolate)
MIC not defined;
linezolid used at
0.25 g/mL;
increased
streptolysin O
protein secretion
Nase: Hydrolyzes
DNA
Gemmell and
Ford,21 2002
S pyogenes strain
expressing
virulence factors
0.125 to 0.5  MIC;
significantly reduced
DNase activity
pe A, B, and F:
Stimulate immune
system, cause fever
Tanaka et al,23
2005
S pyogenes
M1 (clinical
isolate)
MIC not defined;
linezolid used at
0.25 g/mL;
reduced Spe B and
F protein secretion
Coyle et al,24
2003
Spe A–producing
S pyogenes
MIC not defined;
linezolid used at
600 mg q12h;
reduced Spe A
secretion, either
alone or in
combination with
penicillin or
clindamycin
IC: Inhibits innate
immune system
Tanaka et al,23
2005
S pyogenes
M1 (clinical
isolate)
MIC not defined;
linezolid used at
0.25 g/mL;
increased SIC
protein secretion
sp2: Immune system
activator
Tanaka et al,23
2005
S pyogenes
M1 (clinical
isolate)
MIC not defined;
linezolid used at
0.25 g/mL;
increased Isp2
protein secretion
DNase deoxyribonuclease; Isp2 immunogenic secreted protein 2; MICminimum inhibitory concentration;
SIC  streptococcal inhibitor of complement-mediated lysis; Spe  streptococcal pyrogenic exotoxin.example, SLO was increased by 2-fold to more than 8-fold by all of those agents
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which inhibits the innate immune system, and immunogenic secreted protein 2, an
immune system activator, were increased by all protein synthesis inhibitors (4-fold to
more than 8-fold, and 2-fold to more than 8-fold, respectively). The induction of
toxin production was unique to protein synthesis inhibitors; these effects were not
observed with other classes of antibiotics including peptidoglycan synthesis inhibi-
tors, DNA replication inhibitors, or RNA polymerase inhibitors. Clindamycin-
induced increases in SLO and other genes were also accompanied by increases in the
corresponding mRNAs, and were observed in 5 different strains of S pyogenes that
cause toxic shock–like syndrome.
Coyle et al24 used an in vitro pharmacodynamic model to compare the effects of
penicillin (4,000,000 U q4h), clindamycin (900 mg q8h), and linezolid (600 mg
q12h), alone or in combination, on the growth and production of Spe A in 2 S pyogenes
isolates (Table II). In both strains, 99% killing by penicillin alone was reached
within 4 to 6 hours; penicillin-containing combinations required 8 to 24 hours, and
clindamycin and linezolid, alone or in combination, required 24 hours to achieve that
end point. However, Spe A production was increased by 1 hour after treatment with
penicillin alone, whereas it was decreased using all other regimens that contained
clindamycin and/or linezolid.
In Vitro Studies With Host Immune Cells
Eight articles were found that examined the effects on linezolid on toxin-induced
cytokine release, and these studies are summarized below.
The uptake and intracellular activity of linezolid has been tested in vitro in
phagocytic cells (polymorphonuclear leukocytes [PMNs]) and, to a lesser extent,
non-phagocytic cells. Pascual et al25 demonstrated that, at concentrations up to 40
g/mL, linezolid was rapidly taken up by human PMNs and McCoy cells, and peak
intracellular concentrations slightly exceeded those outside the cells. The uptake was
unaffected by temperature or cell viability, which suggests that it occurred via a
passive mechanism. Ballesta et al26 also found that concentrations of linezolid as high
as 20 g/mL did not significantly affect phagocytosis by PMNs of strains of MSSA,
RSA, and Enterococcus faecalis (both vancomycin-resistant and vancomycin-suscep-
ible strains). In addition, preincubation of PMNs with linezolid did not affect their
roduction of superoxide or hydrogen peroxide radicals, which are integral to the
actericidal mechanism of PMNs. Naess et al27 demonstrated that, at concentrations
between 10 and 160 g/mL, linezolid did not significantly affect chemotaxis,
hagocytosis, or respiratory burst of PMNs. Moreover, linezolid had no effect on
NF- production by peritoneal macrophages.22
Because TSST-1 causes overproduction of proinflammatory cytokines such as
NF-, interferon- (IFN-), and interleukin (IL)–2,28 Kushiya et al29 examined the
ffects of a range of antibiotics on the production of these cytokines by peripheral
lood mononuclear cells (PBMC) stimulated with 10 ng/mL TSST-1. Of the antibi-
tics tested (all at 10 and 40 g/mL), only some of the macrolides and related agents
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Current Therapeutic Researchsuppressed TSST-1–induced cytokine production at either of the tested concentra-
tions, and linezolid had no significant effect.
More recently, Pichereau et al30 have tested the effects of a range of antibiotics
including linezolid, clindamycin, azithromycin, vancomycin, trimethoprim–sulfame-
thoxazole, tigecycline, and daptomycin on cytokine production elicited by various
staphylococcal toxins in PBMCs. At a concentration of 100 ng/mL, PVL, TSST-1,
SEA, and -hemolysin each induced, to varying extents, production of TNF-,
IL-1, IL-6, IFN-, and IL-8. For example, PVL tended to be most effective in
stimulating production of TNF- and IL-8, whereas SEA and TSST-1 tended to be
more effective at stimulating production of IL-6, IFN-, and IL-1 (differences
etween the amount of stimulation for each cytokine not statistically significant).
hen antibiotics were added at concentrations corresponding to their peak serum
oncentrations, linezolid (25 g/mL) was overall the most effective antibiotic for
reducing TNF- and IL-8 elicited by PVL, TSST-1, SEA, and -hemolysin (P 0.05
ompared with no antibiotic). Trimethoprim–sulfamethoxazole (1 and 34 g/mL)
was most effective for reduction of IL-1 elicited by TSST-1, SEA, and -hemolysin.
Tigecycline (1 g/mL) was most effective for reduction of IL-6 and IFN- by all 4
toxins. All other tested antibiotics had inconsistent and variable effects on toxin
production at peak serum concentrations. At even higher concentrations (50
g/mL), all antibiotics tended to reduce cytokine production. The concentration
dependence of the effects of each antibiotic for reducing TNF- and IFN- was also
ested at concentrations between 5 and 100 g/mL. Concentration-dependent sup-
ression of cytokine release was most evident for trimethoprim–sulfamethoxazole,
igecycline, and clindamycin, and concentration dependence was also significant for
inezolid and azithromycin; however, no such relationship was found for the other
ested antibiotics.
Garcia-Roca et al31 also tested the effects on PBMC of linezolid and erythromycin
t concentrations between 1 and 30 g/mL, although those researchers used LPS, a
gram-negative bacterial endotoxin (100 ng/mL), to induce inflammatory cytokine
release by these cells. At 10 and 30 g/mL, the 2 drugs exhibited a modest reduction
n LPS-induced PBMC release of proinflammatory cytokines including TNF-,
IL-1, IL-1 receptor antagonist (IL-1ra), and IL-6.
Two studies have tested the effects of linezolid on LPS-stimulated whole blood
from healthy volunteers. Takahashi et al32 found that in blood samples stimulated
ith 10 g/mL LPS, levels of TNF- were reduced by linezolid added at concen-
trations between 2 and 15 g/mL, whereas reductions in levels of IFN- were found
at concentrations between 4 and 15 g/mL. Levels of IL-10 and monocyte chemoat-
tractant protein-1 were not affected by linezolid at any of those concentrations.32
Levels of LPS were unaffected by linezolid, thereby excluding the possibility that
linezolid might have acted to reduce LPS availability. Lambers et al33 tested the
ffects of linezolid (13 g/mL) on both mRNA and protein levels for TNF-, IL-6,
and IL-8, and mRNA levels only for IL-1, in whole blood stimulated with LPS.
Those researchers argued that previous studies had used LPS levels that were far
higher than what might be expected in patients with gram-negative sepsis, and,
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mRNA for all of these cytokines were increased up to several thousand-fold by LPS
stimulation. Linezolid treatment significantly suppressed TNF-, IL-6, IL-8, and
IL-1 mRNA expression after 2 and 4 hours. However, there was little effect of
inezolid treatment on supernatant cytokine protein levels compared with the LPS-
nly controls (reduction in IL-6 protein secretion at 2 hours but not at 4 hours).
In Vivo Studies in Preclinical Animal Models
Mouse Model of Pulmonary Infection
Six articles were found that examined the immunomodulatory effects on linezolid
in animal models, and these are summarized below.
Yanagihara et al34 compared the effects of linezolid, vancomycin, and teicoplanin
n a murine model of hematogenous pulmonary infection with MRSA or vancomycin
ntermediate S aureus (VISA; vancomycin MIC, 8–16 g/mL). All antibiotics were
delivered via intraperitoneal injection twice a day at a dose of 100 mg/kg body weight
per day, beginning 24 hours after inoculation. Compared with treatment with either
vancomycin or teicoplanin, treatment with linezolid significantly improved survival
in VISA-infected mice. Lung tissues of mice infected with VISA treated with
linezolid showed less histopathologic inflammatory damage than did those treated
with vancomycin or teicoplanin. Bacterial numbers detected in lung homogenates
were significantly reduced compared with vancomycin in the MRSA-infected mice.
In a separate study, Yanagihara et al35 compared the effects of linezolid and
vancomycin (100 mg/kg/d IP twice daily for each) on a PVL-positive MRSA strain in
the same mouse pulmonary infection model. Again, compared with vancomycin,
linezolid significantly reduced the number of viable bacteria and the amount of
histopathologic inflammatory damage. Compared with control, levels of TNF-,
IL-1, and macrophage inflammatory protein-2 were significantly reduced by each
antibiotic. Levels of each cytokine were numerically lower in the linezolid group
compared with the vancomycin group; however, the differences were not statistically
significant.
In a more recent study, Akinnusi et al36 compared the effects of linezolid (80
mg/kg IV q12h) and vancomycin (110 mg/kg IV q12h) on pulmonary innate
immune system responses in a mouse model of MRSA infection. In that study, no
significant differences were found between linezolid and vancomycin insofar as
eradication of the pathogens. Furthermore, no differences were found in various
measures of inflammation that included histologic damage, numbers of leukocytes in
bronchoalveolar lavage (BAL) fluid, concentrations of cytokines (IL-6 and monocyte
chemotactic protein-5), matrix metalloproteinase-9 and myeloperoxidase activity
(inflammatory mediators) in BAL fluid, and the rate of apoptosis in neutrophils
isolated from BAL fluid.
Piglet Model of Ventilator-Associated Pneumonia
Luna et al37 compared the effects of linezolid (300 mg q8h), vancomycin (500 mgq6h), and teicoplanin (200 mg q12h for 3 doses, then once daily) in mechanically
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Current Therapeutic Researchventilated piglets infected with MRSA. Treatment with linezolid resulted in signif-
icantly enhanced survival when compared with no treatment; however, no difference
was noted when compared with treatment with vancomycin or teicoplanin. Compared
with untreated controls, the percentage of animals with MRSA-negative blood
cultures or lung fluids was significantly reduced in the linezolid group but not in the
other treatment groups. Serum concentrations of C-reactive protein (a marker of
systemic inflammation), TNF-, and IL-6, and lung fluid levels of TNF- and IL-6
ere lower in treated compared with untreated animals; however, no differences
etween treatment groups were observed.
In a recent study, Martinez-Olondris et al38 compared the effects of linezolid
15 mg/kg q12h) versus vancomycin provided either twice daily (10 mg/kg) or as
continuous infusion (1 g; initial bolus of 250 mg over 60 minutes) in mechan-
cally ventilated piglets infected with PVL-negative MRSA. Compared with
ntreated controls after 96 hours, all treatments significantly reduced MRSA-
ositive cultures in BAL specimens, whereas only linezolid and twice-daily
ancomycin significantly reduced MRSA-positive cultures from postmortem lung
issues. In histopathology samples, all treatments significantly reduced the se-
erity and extent of inflammation; however, severe inflammation was significantly
educed only in linezolid-treated animals. No significant differences between
roups were observed for serum concentrations of proinflammatory cytokines
TNF-, IL-6, and IL-8). The ratio of concentrations between lung tissue and
serum reflected significantly greater tissue penetration of linezolid when com-
pared with either vancomycin treatment group.
Rat Uterine Model of Intraperitoneal Adhesion
Inflammation is often associated with abnormal healing and scar tissue forma-
tion. In one study, in vivo immunomodulatory effects of linezolid were assessed
in the absence of an administered pathogen. Aytan et al39 tested the ability of
rally administered linezolid to prevent intraperitoneal adhesions induced by
auterizing injury in the uterine horn of the rat. Adhesions are commonly caused
y injury such as surgical trauma, and their formation involves an influx of
nflammatory cells and inhibition of fibrinolysis.40 In initial dose–response stud-
ies using doses between 5 and 150 mg/kg/d, a dose of 100 mg/kg/d was found to
be the minimum effective dose to significantly reduce adhesion formation. Treat-
ment was more effective when linezolid treatment was initiated 3 days before
surgery and continued for 14 days after surgery, compared with either presurgical
treatment alone or restriction of the postsurgical treatment period to 7 days.
Although no pathogen was administered, the protective effect of linezolid in this
model could be due to its antimicrobial property.
Clinical Study in Humans
One study was found that examined the short-term effect of linezolid treatment on
levels of IL-1ra, IL-6, and transforming growth factor-1 in inflammatory periapical
esions in patients in whom endodontic treatment had failed.41 In total, 22 patients
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B.A. Diep et al.were assigned to receive either placebo (n  11) or oral linezolid (n  11) at 600 mg
wice daily for 5 days before the operation to remove the tooth. Compared with
lacebo-treated controls, levels of IL-1ra, but not IL-6 and transforming growth
actor-1, in linezolid-treated patients were significantly reduced. It should be noted
that in 50% of patients (5 of 10) treated with linezolid for 5 days before the operation
to remove the tooth, no bacteria were grown from the periapical lesions, compared
with 11% of patients (1 of 9) in the placebo control group, which indicated that
linezolid treatment exerted an antimicrobial effect.
DISCUSSION
A growing number of in vitro studies support the theory that linezolid may
modulate the production of bacterial toxins. For example, suppression of PVL
production by linezolid has been reported by independent laboratories and has
been observed at subinhibitory concentrations, thus providing strong support for
this phenomenon.9 –11 The evidence supporting linezolid-mediated suppression of
rotein A and of - and -hemolysins has also been confirmed in independent
studies.21,22 However, evidence suggesting effects of linezolid on production of
ther toxins produced by either S aureus or S pyogenes is less conclusive. For
example, for S aureus, only single studies have provided evidence of linezolid-
mediated suppression of TSST-1,12 coagulase,21 autolysins,22 streptococcal en-
terotoxins A and B,22 or linezolid-mediated increases in PSM production.19 The
tudy that reported PSM induction by linezolid also observed a similar effect with
lindamycin, which seems to contradict a previous study that reported little or no
ffect of subinhibitory concentrations of clindamycin on agr activity in an S aureus
train.42 For S pyogenes, only single studies have reported linezolid-mediated
uppression of protein M,21 DNase,21 and Spe A, B, and F,23,24 or linezolid-
mediated increases in streptococcal inhibitor of complement-mediated lysis and
immunogenic secreted protein 2.23 Although one study suggested that SLO
protein secretion was increased by linezolid,23 another study suggested that its
ctivity was actually decreased.21 It is not clear whether this indicates that
inezolid induces secretion of inactive SLO protein or whether there might have
een different effects on the bacterial strains used in each study. Further studies
ill be needed to confirm some of these observations and to resolve the seemingly
ontradictory findings in other studies. Therefore, no firm conclusions can be
rawn until those issues are adequately addressed.
Studies of linezolid effects on immune function suggest that linezolid is unlikely
o have any effects on phagocytes. Contradictory results have been reported insofar as
he effect of linezolid on cytokine release elicited by TSST-1.29,30 The differences
between these studies may be attributable to the differences in the tested concentra-
tions of this toxin (10 vs 100 ng/mL). To date, only a single study has provided
evidence for linezolid-mediated suppression of cytokine release induced by PVL,
SEA, and -hemolysin.30 Three studies have provided evidence for linezolid-
mediated suppression of LPS-induced cytokine expression by immune cells,31–33although the magnitude of the reported effects was substantially different be-
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studies are related to the difference between the nature and/or concentrations of
agents used to induce cytokine release and/or other methodologic differences.
Moreover, it is difficult to interpret the relevance of linezolid effects on cytokine
production induced by LPS, a gram-negative bacterial toxin.
In vivo data from preclinical animal studies and a single clinical study in humans
are limited and equivocal insofar as a potential role for linezolid in modulating the
host inflammatory response. Two each of the studies in mice34,35 and in piglets37,38
were designed to test the antibacterial efficacy of linezolid; thus, it is difficult to
differentiate possible direct immunomodulatory effects from those that might have
occurred indirectly as a result of efficacious antimicrobial treatment. Moreover, the
only study in mice that focused more carefully on immunomodulatory activity also
reported comparable efficacy of linezolid and vancomycin,36 which directly conflicts
ith the previous studies. It is not clear whether that difference was due to differences
n the bacterial strain, drug dosages, or other details of the experiments. The study
f linezolid-mediated inhibition of adhesion formation in the rat39 had been designed
to test effects of linezolid unrelated to infection; thus, it did not include an inoculum.
However, the possibility that the efficacy of linezolid in that model might be related
to control of postsurgical infection was not directly addressed. It is noteworthy that
the minimum effective dose was similar to that used for antimicrobial therapy in the
murine pulmonary infection model. Future studies of linezolid-mediated immuno-
modulation should test the effects of this antibiotic either at subinhibitory dosages in
an animal infection model or in a noninfective animal model of inflammation. In
either case, inclusion of an unrelated antimicrobial agent as a control would also aid
in interpretation of the results.
The precise mechanism(s) underlying the clinical efficacy of any antimicrobial
agent is an important factor in directing appropriate treatment decisions. Nev-
ertheless, given these limitations in preclinical studies, it is not surprising that
evidence for immunomodulatory effects in clinical studies are almost nonexistent.
Only one small clinical study has provided equivocal evidence that linezolid has
the potential to affect cytokine levels within infected tissues.41 However, lin-
ezolid also reduced the numbers of active pathogens in those patients, again
raising the possibility that the immunomodulatory effects resulted from effica-
cious antimicrobial treatment rather than any direct effect of linezolid on immune
function. It seems likely that more compelling evidence from preclinical studies
may be needed to design clinical studies that are appropriate to address the
possible benefits directly associated with linezolid effects on bacterial toxin
production and/or immunomodulation.
CONCLUSION
A growing body of evidence supports the possibility that linezolid affects (in-
creases or decreases) toxin production in clinically relevant pathogens such as
S aureus and streptococci; however, the results of these experiments seem to
depend on the bacterial strain used, the replication stage of the bacteria (early vs
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experiments. Data suggest that linezolid is passively taken up by PMNs and even
at high concentrations does not inhibit PMN function (phagocytosis, chemotaxis,
or respiratory burst). Data on the direct effect of linezolid on host immune
responses to microbial antigens, including gram-negative LPS, are limited and
equivocal. The only study in humans that examined the immunomodulatory
effect of linezolid was in patients with periradicular lesions of the tooth, and the
observed effect of linezolid could have been due in part to inhibition of bacterial
replication. More research will be needed to confirm and extend these studies.
Research will also be needed to explore the potential mechanisms, extent of
secondary immunomodulatory effects, and potential clinical relevance of those
findings for linezolid.
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